Liver injury caused by antiviral agents for COVID-19
10.3760/cma.j.issn.1674-2397.2020.02.004
- VernacularTitle:新型冠状病毒肺炎治疗中抗病毒药物引起的肝损伤
- Author:
Ping YANG
1
;
Kaijin XU
;
Limin KONG
;
Na CHEN
;
Saiping JIANG
;
Xiaoyang LU
Author Information
1. 浙江大学医学院附属第一医院药学部，杭州 310003
- From:
Chinese Journal of Clinical Infectious Diseases
2020;13(2):102-108
- CountryChina
- Language:Chinese
-
Abstract:
Antiviral therapy is important for COVID-19. Currently, the anti-2019-nCoV drugs in clinical trials include broad-spectrum antiviral drugs (alpha interferon and ribavirin), hemagglutinin inhibitors (arbidol), human immunodeficiency virus protease inhibitors (lopinavir/ritonavir and darunavir/cobicistat), nucleoside analogues (favipiravir and remdesivir) and antimalarial drug (chloroquine); while liver damage may occur in some patients with the medication. This article reviews the research on liver damage associated with anti-2019-nCoV drugs, aiming at promoting the safe and effective antiviral therapy for COVID-19 patients.
